ResMed Stock

$257.92

0.59% yesterday

NYSE, Jul 18, 10:10 pm CET

ISIN

US7611521078

Symbol

RMD

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

ResMed Stock price

$257.92

+54.91 27.05% 5Y

NYSE, Closing price Fri, Jul 18 2025

+1.50 0.59%

ISIN

US7611521078

Symbol

RMD

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Health

Industry

Medical specialties

Key metrics

Basic

Market capitalization

$37.8b

Enterprise Value

$37.6b

Net debt

positive

Cash

$932.7m

Shares outstanding

146.6m

Valuation (TTM | estimate)

P/E

28.9 | 26.9

P/S

7.5 | 7.3

EV/Sales

7.5 | 7.3

EV/FCF

24.1

P/B

6.8

Dividends

DPS

$2.12

Yield 1Y | 5Y

0.8% | 0.8%

Growth 1Y | 5Y

10.4% | 6.3%

Payout 1Y | 3Y

27.8% | 29.3%

Increased

4 Years

Financials (TTM | estimate)

Revenue

$5.0b | $5.2b

EBITDA

$1.7b | $1.9b

EBIT

$1.6b | $1.7b

Net Income

$1.3b | $1.4b

Free Cash Flow

$1.6b

Growth (TTM | estimate)

Revenue

9.5% | 10.4%

EBITDA

23.9% | 33.1%

EBIT

25.0% | 25.5%

Net Income

37.0% | 37.7%

Free Cash Flow

45.6%

Financial Health

Equity Ratio

70.8%

Return on Equity

21.0%

ROCE

24.3%

ROIC

21.9%

Debt/Equity

0.1

EPS

$8.9

FCF per Share

$10.6

Short interest

7.8%

Employees

10k

Rev per Employee

$470.0k

As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.

Get Started for Free Today

ResMed Stock Analysis

Unlock Scores for Free

??

23 Analysts have issued a ResMed forecast:

15x Buy

65%

7x Hold

30%

More details on Analyst Estimates Including Price Targets

23 Analysts have issued a ResMed forecast:

Buy

65%

Hold

30%

Sell

Analyst Estimates with Stock Price Targets

Financial data from ResMed

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	5,022 5,022	10% 10% 100%
- Direct Costs	2,071 2,071	2% 2% 41%
Gross Profit	2,950 2,950	15% 15% 59%
- Selling and Administrative Expenses	968 968	6% 6% 19%
- Research and Development Expense	326 326	7% 7% 6%
EBITDA	1,657 1,657	24% 24% 33%
- Depreciation and Amortization	45 45	6% 6% 1%
EBIT (Operating Income) EBIT	1,612 1,612	25% 25% 32%
Net Profit	1,313 1,313	37% 37% 26%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

ResMed Stock News

Positive

Seeking Alpha

●

18 days ago

Top 15 High-Growth Dividend Stocks For July 2025

My Top 15 High-Growth Dividend Stocks outperformed SPY and VIG in June, gaining 6.15% versus SPY's 5.14% and VIG's 3.41%. The list's year-to-date return is 12.59%, beating SPY every month in 2025, though still a bit short of my 12% annualized target. The July 2025 Top 15 stocks offer a 1.38% average dividend yield with an 18.78% 5-year dividend growth rate and are 23% undervalued.

Neutral

GlobeNewsWire

●

18 days ago

Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025

SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2025 on Thursday, July 31, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also...

Positive

The Motley Fool

●

about one month ago

ResMed: A Mixed Bag for Investors Amid Rising Competition

Explore the exciting world of ResMed (RMD 0.64%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

More ResMed News

Company Profile

ResMed, Inc. engages in the development, manufacturing, distribution, and marketing of medical equipment and software solutions. The company operates through the following segments: Sleep and Respiratory Care, and SaaS. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The SaaS segment engages in the supply of business management software as a service to out-of-hospital health providers. Its product portfolio includes devices, diagnostic products, mask systems, headgear and other accessories, and dental devices. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Head office	United States
CEO	Mick Farrell
Employees	9,980
Founded	1989
Website	www.resmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now